EMEA-001214-PIP05-19
Table of contents
Key facts
| Invented name |
Fasenra
|
| Active substance |
Benralizumab
|
| Therapeutic area |
Gastroentology-Hepatology
|
| Decision number |
P/0388/2021
|
| PIP number |
EMEA-001214-PIP05-19
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of eosinophilic esophagitis
|
| Route(s) of administration |
|
| Contact for public enquiries |
AstraZeneca AB
E-mail: paediatrics@astrazeneca.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|